InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(e) Compensatory Arrangements of Certain Officers
On September 25, 2019, the Board of Directors of InVivo Therapeutics Holdings Corp. (the “Company”) granted, under the Company’s 2015 Equity Incentive Plan, 69,000 shares of restricted Common Stock of the Company, $0.00001 par value per share (“Common Stock”), to Richard Toselli, the Company’s Chief Executive Officer, and 47,500 shares of restricted Common Stock to Richard Christopher, the Company’s Chief Financial Officer, (together, the “Grants”) in consideration of Dr. Toselli’s and Mr. Christopher’s service as officers of the Company. The Grants vest 50% on September 25, 2022, assuming continued service to the Company by the relevant officer. The Board of Directors also adopted a form of Restricted Stock Agreement under the 2015 Equity Incentive Plan, which form of Restricted Stock Agreement is attached as Exhibit 10.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
INVIVO THERAPEUTICS HOLDINGS CORP. Exhibit
EX-10.1 2 ex-10d1.htm EX-10.1 nviv_Ex10_1 Exhibit 10.1 INVIVO THERAPEUTICS HOLDINGS CORP. RESTRICTED STOCK AGREEMENT 2015 Equity Incentive Plan This Restricted Stock Agreement (this “Agreement”) is made as of the Grant Date set forth below between InVivo Therapeutics Holdings Corp.,…
To view the full exhibit click
About InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV)
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.
An ad to help with our costs